HHC is sold in gas stations and vape shops with the easy confidence of something that has been tested and approved. It hasn't been. It reached the market through a gap in how hemp products are regulated, and the honest summary of the research is that there is very little of it.
Key Takeaways
- HHC is semi-synthetic — manufactured from hemp-derived CBD, not extracted from the plant
- It’s a mixture of two isomers with quite different activity, in ratios makers don’t disclose
- Human safety data is thin because it’s only been in wide use a few years
- One small hospital study found HHC use preceding 34% of first-episode psychosis admissions — a signal, not proof
What HHC Is
Hexahydrocannabinol is a cannabinoid closely related to THC, distinguished by hydrogenation — the same chemistry, broadly, that turns a liquid oil into a solid fat. It was first described chemically in 1940, but it only became a consumer product recently. It was the first semi-synthetic cannabinoid to appear on the European market, produced from CBD through cyclization and hydrogenation [1].
It's worth being precise about "semi-synthetic," because product marketing works hard to blur it. Trace HHC does occur in cannabis, but not in amounts anyone could harvest. What's in a vape cartridge was made in a lab from a hemp extract. It is a manufactured compound with a plant-derived starting material — which is a different thing from a plant extract.
Why It Exists at All
HHC exists mostly for legal reasons rather than pharmacological ones. Rules written to permit hemp and its derivatives created room for cannabinoids that are chemically distinct from delta-9 THC but produce comparable effects. HHC filled that room, alongside delta-8 and a growing list of others.
The consequence is a product category defined by what regulation doesn't yet cover. Manufacturing isn't standardized, potency isn't verified, and independent testing has repeatedly found products whose contents don't match their labels. Several US states and European countries have since restricted or banned HHC — but "currently legal where you live" describes regulatory timing, not safety.
What It Does — and What Isn't Known
HHC is psychoactive and acts on the CB1 receptor, so its effects broadly resemble THC's: altered perception, euphoria, and at higher amounts anxiety, a racing heart, disorientation, and nausea.
The complication is that HHC isn't one molecule. Manufacturing produces two isomers, (9R)-HHC and (9S)-HHC, which engage the CB1 receptor quite differently — one is considerably more active than the other [2]. The ratio depends on the process and is essentially never disclosed. Two products with identical labels can therefore differ substantially in strength, which makes the usual advice about starting low hard to act on: there is no stable reference point.
The Psychosis Signal
This is the finding drawing the most clinical attention, and it deserves to be reported carefully rather than dramatically.
A retrospective review at a single Irish hospital over 21 months found that of 47 people admitted with a first episode of psychosis, 16 — about 34% — had used HHC in the two weeks beforehand, and 7 had used HHC only [3].
What that does not establish is cause. It was one hospital in one region, the substance use was self-reported with no confirmatory urine testing, and the authors are explicit that it is an observed association. They also note their figures likely understate HHC use, since people don't always report it. So: a signal worth watching, not a settled finding.
The wider context is better established. High-potency cannabinoids are associated with psychotic symptoms in susceptible people [4], and a compound of undisclosed and variable potency is a poor fit for anyone with a personal or family history of psychosis, bipolar disorder, or schizophrenia. If cannabinoid use has been followed by paranoia, hearing things, or losing the thread of what's real, that warrants medical attention now rather than later.
Drug Testing
People ask whether HHC shows up on a drug test, and the accurate answer is: unreliably, in both directions. Standard immunoassay panels are built to find THC metabolites, and HHC is metabolized differently, so it may not trigger a routine screen. But laboratory methods capable of detecting semi-synthetic cannabinoids exist and are in use, and products sold as HHC frequently contain delta-9 THC as well.
Which is to say it should not be treated as a way around a test. If you're facing testing that matters — employment, court, a treatment program — the variable worth attending to isn't the panel. Our page on how long cannabis stays in your system covers the general picture for THC.
When it's worth talking to someone
Most people reading this just want to know what HHC is, and that's a reasonable thing to want to know. But two situations are worth naming. The first is psychiatric: if cannabinoid use has been followed by paranoia, hallucinations, or a period where things stopped feeling real, that's a medical matter and it doesn't improve by being ignored.
The second is when use has quietly become load-bearing — managing anxiety, sleep, or a mood that predates it. That's where treating the substance use and the underlying condition together matters, because addressing either one alone usually doesn't hold. Our clinical work centers on co-occurring mental health conditions alongside substance use, and that's the right conversation to have here.
If someone is in acute distress — unable to tell what's real, frightened, agitated, or at risk of harming themselves — call 911 or go to an emergency department. If this brings up thoughts of suicide or self-harm, call or text 988, the Suicide & Crisis Lifeline.
FAQs
- What is HHC?
- Hexahydrocannabinol is a semi-synthetic cannabinoid — not something extracted from the plant in meaningful quantities, but manufactured in a lab, typically from hemp-derived CBD through cyclization and hydrogenation. It was the first semi-synthetic cannabinoid to appear on the European market and is sold widely in vapes, edibles, and flower sprayed with it.
- Is HHC natural?
- Not in any practical sense. Trace amounts occur in cannabis, but the HHC in commercial products is made industrially from CBD. Marketing that presents it as a natural plant compound is misleading.
- Is HHC stronger than THC?
- It depends on the isomer, which is part of the problem. HHC is produced as a mixture of two forms, (9R)-HHC and (9S)-HHC, that bind the CB1 receptor quite differently — one is substantially more active than the other. The ratio varies by manufacturer and is generally not disclosed, so two products labeled identically can behave very differently.
- Is HHC legal?
- Its status is contested and shifting. It has been sold through the gap opened by hemp-derived cannabinoid rules rather than through any affirmative approval, and a number of US states and European countries have moved to restrict or ban it. Legality also is not a safety statement — it reflects regulatory timing, not evidence of harmlessness.
- Does HHC show up on a drug test?
- Not reliably, and this cuts both ways. Standard immunoassay panels look for THC metabolites, and HHC metabolizes differently, so it may not trigger them. But laboratory methods that do detect semi-synthetic cannabinoids exist and are in use, and products sold as HHC often contain some delta-9 THC as well. Nobody should treat HHC as test-proof.
- Is HHC safe?
- There is not enough human data to say. It has been in wide consumer use for only a few years, the products are largely unregulated, and independent testing has repeatedly found contents that do not match labels. Absence of evidence of harm is not evidence of safety — it mostly reflects how little has been studied.
- Can HHC cause psychosis?
- That has not been established. One retrospective single-hospital study found HHC use preceding 34% of first-episode psychosis admissions, which is a signal worth taking seriously, but it was small, self-reported, without confirmatory testing, and cannot show cause. What is better established is that high-potency cannabinoids are associated with psychotic symptoms in vulnerable people — which is reason for caution, particularly for anyone with a personal or family history of psychosis.
- Does insurance cover treatment for cannabinoid use and co-occurring mental health conditions?
- Most major plans cover medically necessary treatment for substance use and mental health conditions together. You can verify coverage for free in a few minutes.
Sources
- Russo F, Vandelli MA, Biagini G, et al. Scientific Reports (2023), NIH/PMC. Synthesis and characterization of hexahydrocannabinol (HHC), the first semi-synthetic cannabinoid on the EU market.
- Nasrallah DJ, Garg NK. ACS Chemical Biology (2023), NIH/PMC. Studies Pertaining to the Emerging Cannabinoid Hexahydrocannabinol (HHC).
- O’Mahony et al. BJPsych Bulletin (2025), NIH/PMC. Hexahydrocannabinol use among first-episode psychosis admissions.
- National Institute on Drug Abuse (NIDA). Cannabis (Marijuana).
This article is for informational purposes only and is not a substitute for professional medical advice. It is not guidance on obtaining or using any substance, or on drug testing.
Written by
Executive Director
Dominic Perry is a Licensed Clinical Social Worker (LCSW), Licensed Clinical Alcohol and Drug Counselor (LCADC), Master Addiction Counselor (MAC), and DOT Substance Abuse Professional (SAP) with approximately eight years of experience in behavioral health and substance use treatment. Dominic began his work with Virtue as a therapist at the Corbett residential facility before progressing into leadership, and now serves as Executive Director of Virtue Recovery Center – Outpatient in Las Vegas. He earned his Bachelor of Social Work from UNLV and his Master of Social Work from the University of Nevada Reno.
Read Full Bio →
